Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Mission Pharmacal Company
EIR
•Mission Pharmacal Company•May 4, 2017

Mission Pharmacal Company – FDA EIR, May 4, 2017

Record Details

An FDA inspection of Mission Pharmacal Co. in Boerne, TX, was conducted from May 1 to May 4, 2017. This surveillance inspection focused on post-marketing adverse drug experiences and evaluated the firm's Quality and Laboratory Control systems for prescription/OTC drug products, dietary supplements, and medical devices. Overall, no significant deficiencies were observed, and no FDA-483 (Inspectional Observations) was issued. The inspection confirmed that a blend uniformity testing deficiency noted in a previous 2014 inspection had been corrected. However, during the review of dietary supplement operations under 21 CFR 111 (Current Good Manufacturing Practice), two matters were discussed with management. First, the website for Calcet Petites, a dietary supplement, contained impermissible disease claims, specifically mentioning "treatment of osteoporosis." Second, the firm initially struggled to provide raw material receiving records for folic acid within the required retention period, highlighting a need for improved document accessibility. In response, Mission Pharmacal Co. management promptly initiated revisions to the website to remove the inappropriate claims and committed to updating their record retention procedures to ensure documents are readily available as required by regulations.

Company
Mission Pharmacal Company
Inspection date
May 4, 2017
Product type
drugs
Office
Dallas District Office
People
  • Stephen D. Brown (Principal Consultant)
  • John Noe (company_representative)
  • Neill Walsdorf (recipient)
  • John M. Simonick (recipient)
  • Rian L. Pope (investigator)
View Company Profile

ID · 3401cfdc-0828-4576-a5a3-4e3347c881be

Violation Codes5
21 CFR 11121 CFR 111.18021 CFR 820.19821 CFR 21121 CFR 111.605

Full citation text and observation details available on the Dashboard.

Other documents for Mission Pharmacal Company
  • 483 - 2022-09-22September 22, 2022
  • 483 - 2019-04-04April 4, 2019
  • EIR - 2018-09-20September 20, 2018
  • EIR - 2016-04-04April 4, 2016
  • EIR - 2014-02-07February 7, 2014

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Mission Pharmacal Company
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.